Abstract
Attention-deficit hyperactivity disorder (ADHD), has been traditionally considered a neurodevelopmental disorder affecting children and adolescents characterized by inattention, hyperactivity, disruptive behavior, and impulsivity. Although still debated, it is evident that ADHD is also present in adulthood, but this diagnosis is rarely carried out, mainly for the frequent comorbidity with other psychiatric and/or substance abuse disorders. Given the need to shed more light on the pharmacological treatment of ADHD, we performed a naturalistic review to review and comment on the available literature of ADHD treatment across the lifespan. Indeed, stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants, although requiring some weeks to be fully effective, are useful when a substance abuse history is detected. In any case, the pharmacological management of ADHD appears to be still largely influenced by the individual experience of the clinicians. Further longitudinal studies with a careful and detailed characterization of participants across different phases of the lifespan are also required to provide relevant confirmations (or denials) regarding pharmacological treatments amongst the different age groups.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbas G, Jorgensen RA, Lindor KD (2010) Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 6:313–319. https://doi.org/10.1038/nrgastro.2010.62
Abela AR, Chudasama Y (2014) Noradrenergic α2A-receptor stimulation in the ventral hippocampus reduces impulsive decision-making. Psychopharmacology 231:521–531
Adler LA, Gorny SW (2015) Pilot study of Droxidopa with Carbidopa in adults with ADHD. J Atten Disord 23(2):189–198. https://doi.org/10.1177/1087054715580393
Adler LA, Resnick S, Kunz M, Devinsky O (1995) Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 31(4):785–788
Agenzia Italiana del Farmaco (2007) Determinazione 19 aprile 2007 — Supplemento ordinario alla ‘‘Gazzetta Ufficiale, n. 95 del 24 aprile 2007 — Serie generale “Autorizzazione all’immissione in commercio della specialità medicinale per uso umano Ritalin® e “Autorizzazione all’immissione in commercio della specialità medicinale per uso umano Strattera®. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2007-04-24&atto.codiceRedazionale=07A03653&elenco30giorni=false. Accessed 31st Aug 2020
Agenzia Italiana del Farmaco (2015a) Determina n. 488/2015 “Inserimento del medicinale per uso umano «Metilfenidato (Ritalin)» nell'elenco dei medicinali erogabili a totale carico del Servizio sanitario nazionale, ai sensi della legge 23 dicembre 1996, n. 648, per il trattamento del disturbo da deficit dell'attenzione e iperattività (ADHD) negli adulti già in trattamento farmacologico prima del compimento del diciottesimo anno di eta'.” In: Gazzetta Ufficiale Serie Generale n.107 del 11.5.2015. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2015-05-11&atto.codiceRedazionale=15A03435&elenco30giorni=false. Accessed 31 Aug 2020
Agenzia Italiana del Farmaco (2015b) Determina n. 860/2015 “Rettifica della determina 27 aprile 2015, n. 488/2015 concernente l'inserimento del medicinale per uso umano «Metilfenidato (Ritalin)» nell'elenco dei medicinali erogabili a totale carico del Servizio sanitario nazionale, ai sensi della legge 23 dicembre 1996, n. 648, per il trattamento del disturdo da deficit dell'attenzione e iperattivita' (ADHD) negli adulti gia' in trattamento farmacologico prima del compimento del diciottesimo anno di eta'.” In: Gazzetta Ufficiale Serie Generale n.168 del 22–7–2015. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2015-07-22&atto.codiceRedazionale=15A05618&elenco30giorni=false. Accessed 31 Aug 2020
Agnew-Blais JC, Polanczyk GV, Danese A, Wertz J, Moffitt TE, Arseneault L (2016) Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiat 73(7):713–720. https://doi.org/10.1001/jamapsychiatry.2016.0465
Alamo C, López-Muñoz F, Sánchez-García J (2016) Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd). Actas Esp Psiquiatr 44(3):107–112 (Epub 2016 May 1)
American Psychiatric Association Committee on Nomenclature and Statistics (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Press, Washington DC
Amiri S, Farhang S, Ghoreishizadeh MA, Malek A, Mohammadzadeh S (2012) Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol 27(1):76–81. https://doi.org/10.1002/hup.1274
Arnold LE, Hodgkins P, Caci H, Kahle J, Young S (2015) Effect of treatment modality on long-term outcomes in attention- deficit/hyperactivity disorder: a systematic review. PLoS ONE 10(2):e0116407. https://doi.org/10.1371/journal.pone.0116407
Arnsten AFT, Jin LE (2012) Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med 85:45–55
Arnsten AFT, Pliszka SR (2011) Catecholamine Influences on prefrontal cortical function: relevance to treatment of attention deficit hyperactivity disorder and related disorders. Pharmac Biochem Behav 99:211–216
Asherson P, Young AH, Eich-Höchli D, Moran P, Porsdal V, Deberdt W (2014) Differential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. Curr Med Res Opin 30(8):1657–1672. https://doi.org/10.1185/03007995.2014.915800
Ashok AH, Mizuno Y, Volkow ND, Howes OD (2017) Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiat 74(5):511–519. https://doi.org/10.1001/jamapsychiatry.2017.0135
Bagot KS, Kaminer Y (2014) Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 109(4):547–557. https://doi.org/10.1111/add.12460
Baldwin DS, Papakostas GI (2006) Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry 67(Suppl. 6):9–15
Bálint S, Czobor P, Komlósi S, Mészáros A, Simon V, Bitter I (2009) Attention-deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. Psychol Med 39(8):1337–1345. https://doi.org/10.1017/S0033291708004236
Bartu A, Dusci LJ, Ilett KF (2009) Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol 67(4):455–459. https://doi.org/10.1111/j.1365-2125.2009.03366.x
Becker SP, Marshall SA, McBurnett K (2014) Sluggish cognitive tempo in abnormal child psychology: an historical overview and introduction to the special section. J Abnorm Child Psychol 42(1):1–6. https://doi.org/10.1007/s10802-013-9825-x
Becker SP, Burns GL, Garner AA, Jarrett MA, Luebbe AM, Epstein JN, Willcutt EG (2018) Sluggish cognitive tempo in adults: psychometric validation of the Adult Concentration Inventory. Psychol Assess 30(3):296–310. https://doi.org/10.1037/pas0000476
Belkin MR, Schwartz TL (2015) Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder. Drugs Context 4:212286. https://doi.org/10.7573/dic.212286
Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW (2002) Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 42(11):1219–1227. https://doi.org/10.1177/009127002762491307
Bello NT (2015) Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents. Patient Pref Adher 9:877–885
Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE et al (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 60(10):1111–1120. https://doi.org/10.1016/j.biopsych.2006.04.022
Bidwell LC, McClernon FJ, Kollins SH (2011) Cognitive enhancers for the treatment of ADHD. Pharmacol Biochem Behav 99(2):262–274. https://doi.org/10.1016/j.pbb.2011.05.002
Biederman J, Mick E, Faraone SV (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157(5):816–818. https://doi.org/10.1176/appi.ajp.157.5.816
Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T et al (2002) Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 159(1):36–42
Bodner RA, Lynch T, Lewis L, Kahn D (1995) Serotonin syndrome. Neurology 45(2):219–223. https://doi.org/10.1212/WNL.45.2.219
Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S et al (2012) The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 24(1):23–37
Boreman CD, Arnold LE (2003) Hallucinations associated with initiation of guanfacine. J Am Acad Child Adolesc Psychiatry 42(12):1387. https://doi.org/10.1097/00004583-200312000-00004
Broadley KJ (2010) The vascular effects of trace amines and amphetamines. Pharmacol Ther 125(3):363–375. https://doi.org/10.1016/j.pharmthera.2009.11.005
Canadian ADHD Resource Alliance (CADDRA) (2011) Canadian ADHD practice guidelines (3rd edn). Canadian Attention Deficit Hyperactivity Resource Alliance, Toronto (ON). https://caddra.ca/pdfs/caddraGuidelines2011Chapter07.pdf
Carlson CL, Tamm L, Gaub M (1997) Gender differences in children with ADHD, ODD, and co-occurring ADHD/ODD identified in a school population. J Am Acad Child Adolesc Psychiatry 36(12):1706–1714
Carlson PJ, Merlock MC, Suppes T (2004) Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 6(5):416–420. https://doi.org/10.1111/j.1399-5618.2004.00132.x
Castells X, Blanco-Silvente L, Cunill R (2018) Amphetamines for attention-deficit hyperactivity disorder (ADHD) in adult. Cochrane Database Syst Rev 8:CD007813
Caye A, Rocha TB, Anselmi L, Murray J, Menezes AM, Barros FC et al (2016) Attention-deficit/hyperactivity disorder trajectoriesfrom childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiat 73(7):705–712. https://doi.org/10.1001/jamapsychiatry.2016.0383
Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W (1983) Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 72(1):56–59
Chatterjie N, Stables JP, Wang H, Alexander GJ (2004) Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity. Neurochem Res 29(8):1481–1486. https://doi.org/10.1023/B:NERE.0000029559.20581.1a
Chen Z, Skolnick P (2007) Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 16(9):1365–1377. https://doi.org/10.1517/13543784.16.9.1365
Collins JA, Fauser BC (2005) Balancing the strengths of systematic and narrative reviews. Human Reprod Update 11(2):103–104. https://doi.org/10.1093/humupd/dmh058
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
Croxtall JD (2011) Clonidine extended-release: in attentiondeficit hyperactivity disorder. Paediatr Drugs 13(5):329–336. https://doi.org/10.2165/11208100-000000000-00000
Dell’Osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC (2014) Wake-promoting pharmacotherapy for psychiatric disorders. Curr Psychiatry Rep 16(12):524. https://doi.org/10.1007/s11920-014-0524-2
Dolder CR, Davis LN, McKinsey J (2010) Use of psychostimulants in patients with dementia. Ann Pharmacother 44(10):1624–1632. https://doi.org/10.1345/aph.1P341
Dorrego MF, Canevaro L, Kuzis G, Sabe L, Starkstein SE (2002) A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention deficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 14(3):289–295. https://doi.org/10.1176/jnp.14.3.289
Elbe D, Perel-Panar C, Wicholas L (2016) Manic reaction in a child induced by guanfacine-extended release. J Child Adolesc Psychopharmacol 26(6):566–567. https://doi.org/10.1089/cap.2016.0050
Engberg G, Eriksson E (1991) Effects of alpha-2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in EEDQ-treated rats. Naunyn-Schmiedebergs Arch Pharmacol 343:472–477
Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255–270
Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA (2005) 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7(3):106–113. https://doi.org/10.4088/PCC.v07n0305
Feinberg SS (2004) Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry 65(11):1520–1524. https://doi.org/10.4088/JCP.v65n1113
Felt BT, Biermann B, Christner JG, Kochhar P, Harrison RV (2014) Diagnosis and management of ADHD in children. Am Fam Physician 90(7):456–464
Findling RL, Short EJ, McNamara NK, Demeter CA, Stansbrey RJ, Gracious BL et al (2007) Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(11):1445–1453. https://doi.org/10.1097/chi.0b013e31814b8d3b
Flannery AJ, Becker SP, Luebbe AM (2016) Does emotion dysregulation mediate the association between sluggish cognitive tempo and college students’ social impairment? J Atten Disord 20(9):802–812. https://doi.org/10.1177/1087054714527794
Flannery AJ, Luebbe AM, Becker SP (2017) Sluggish cognitive tempo is associated with poorer study skills, more executive functioning deficits, and greater impairment in college students. J Clin Psychol 73(9):1091–1113. https://doi.org/10.1002/jclp.22406
Foye WO, Lemke TL, Williams DA (1996) Principles of medicinal chemistry. Williams & Wilkins, Baltimore
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, Cormand B, Faraone SV, Ginsberg Y, Haavik J, Kuntsi J, Larsson H, Lesch KP, Ramos-Quiroga JA, Réthelyi JM, Ribases M, Reif A (2018) Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol 10:1059–1088. https://doi.org/10.1016/j.euroneuro.2018.08.001
Gahr M, Freudenmann RW, Eller J, Schonfeldt-Lecuona C (2014) Abuse liability of centrally acting non-opioid analgesics and muscle relaxants - a brief update based on a comparison of pharmacovigilance data and evidence from the literature. Int J Neuropsychopharmacol 17(6):957–959
Gaub M, Carlson CL (1997a) Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population. J Abnorm Child Psychol 25(2):103–111
Gaub M, Carlson CL (1997b) Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 36(8):1036–1045
Ghuman JK, Hutchison SL (2014) Atomoxetine is a second-line medication treatment option for ADHD. Evid Based Ment Health 17(4):108. https://doi.org/10.1136/eb-2014-101805
Goodman DW (2007a) Lisdexamphetamine dymesilate. The first prodrug stimulant. Psychiatry (Edgmont) 4(8):39–45
Goodman DW (2007b) The consequences of attentiondeficit/hyperactivity disorder in adults. J Psychiatr Pract 13(5):318–327. https://doi.org/10.1097/01.pra.0000290670.87236.18
Goodman LS, Gilman AG, Brunton LL, Chabner BA, Knollmann Björn C (2011) Goodman & Gilmans the pharmacological basis of therapeutics, 12th edn. McGraw-Hill Medical, New York
Goss AJ, Kaser M, Costafreda SG, Sahakian B, Fu CH (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74(11):1101–1107. https://doi.org/10.4088/JCP.13r08560
Hardy SE (2009) Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 7(1):34–59. https://doi.org/10.1016/j.amjopharm.2009.02.006
Hashemian F, Mohammadian S, Riahi F, Ghaeli P, Ghodsi D (2011) A comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit- Hyperactivity Disorder (ADHD). Daru 19(3):231–235
Heal DJ, Pierce DM (2006) Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20(9):713–738. https://doi.org/10.2165/00023210-200620090-00002
Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol (Oxford) 27(6):479–496. https://doi.org/10.1177/0269881113482532
Henderson TA, Hartman K (2004) Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics 114(3):895–896. https://doi.org/10.1542/peds.2004-1140
Hodgkins P, Shaw M, Coghill D, Hechtman L (2012) Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 21(9):477–492. https://doi.org/10.1007/s00787-012-0286-5
Horrigan JP, Barnhill LJ (1999) Guanfacine and secondary mania in children. J Affect Disord 54(3):309–314. https://doi.org/10.1016/S0165-0327(98)00183-9
Hurst DL, Lajara-Nanson W (2002) Use of modafinil in spastic cerebral palsy. J Child Neurol 17(3):169–172. https://doi.org/10.1177/088307380201700303
Huss M, Ginsberg Y, Tvedten T, Arngrim T, Philipsen A, Carter K et al (2014) Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther 31(1):44–65. https://doi.org/10.1007/s12325-013-0085-5
Ilieva IP, Hook CJ, Farah MJ (2015) Prescription stimulants’ effects on healthy inhibitory control, working memory, and episodic memory: a meta-analysis. J Cogn Neurosci 27(6):1069–1089. https://doi.org/10.1162/jocn_a_00776
Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (2008) Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry Clin Neurosci 62(2):246. https://doi.org/10.1111/j.1440-1819.2008.01767.x
Ishizuka T, Murotani T, Yamatodani A (2012) Action of modafinil through histaminergic and orexinergic neurons. Vitam Horm 89:259–278. https://doi.org/10.1016/B978-0-12-394623-2.00014-7
Iversen L (2006) Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 147(Suppl. 1):82–88. https://doi.org/10.1038/sj.bjp.0706428
Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ (2008) Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 95(1–2):140–146. https://doi.org/10.1016/j.drugalcdep.2008.01.008
Ji X, Ji J, Zhang H, Li BM (2008) Stimulation of a2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat. Neuropsychopharmacology 33:2263–2271
Kasi PM, Mounzer R, Gleeson GH (2011) Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep Med 2011:952584. https://doi.org/10.1155/2011/952584
Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ (2017) Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry 17(1):302. https://doi.org/10.1186/s12888-017-1463-3
Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S et al (2014) Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 83(4):328–335. https://doi.org/10.1212/WNL.0000000000000615
Kessler S (1996) Drug therapy in attention-deficit hyperactivity disorder. South Med J 89(1):33–38. https://doi.org/10.1097/00007611-199601000-00005
Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK et al (2005) Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 57(11):1442–1451. https://doi.org/10.1016/j.biopsych.2005.04.001
Ketter TA, Yang R, Frye MA (2015) Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder. J Affect Disord 181:87–91. https://doi.org/10.1016/j.jad.2015.04.012
Kim RK, Chayer R (2015) Psychosis associated with guanfacine. J Clin Psychopharmacol 35(2):213. https://doi.org/10.1097/JCP.0000000000000281
Klassen LJ, Katzman MA, Chokka P (2010) Adult ADHD and its comorbidities, with a focus on bipolar disorder. J Affect Disord 124(1–2):1–8. https://doi.org/10.1016/j.jad.2009.06.036
Koblan KS, Hopkins SC, Sarma K, Jin F, Goldman R et al (2015) Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology 40(12):2745–2752
Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (2010) Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 114(1):259–270. https://doi.org/10.1111/j.1471-4159.2010.06750.x
Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L (2008) Treatment of adults with attentiondeficit/hyperactivity disorder. Neuropsychiatr Dis Treat 4(2):389–403
Kooij J, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, Thome J, Dom G, Kasper S et al (2019) Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur psych 56:14–34. https://doi.org/10.1016/j.eurpsy.2018.11.001
Kriikku P, Ojanperä I (2016) The relationship between bupropion and suicide in post-mortem investigations. Forensic Sci Int 266:343–348
Kurlan R (2003) Tourette’s syndrome: are stimulants safe? Curr Neurol Neurosci Rep 3(4):285–288. https://doi.org/10.1007/s11910-003-0004-2
Larsson H, Dilshad R, Lichtenstein P, Barker ED (2011) Developmental trajectories of DSM-IV symptoms of attention- deficit/hyperactivity disorder: genetic effects, family risk and associated psychopathology. J Child Psychol Psychiatry 52(9):954–963. https://doi.org/10.1111/j.1469-7610.2011.02379.x
Lehmann DF, Wojnowicz S (2016) The evergreening of biopharmaceuticals: time to defoliate. J Clin Pharmacol 56(4):383–389. https://doi.org/10.1002/jcph.642
Lenzi F, Cortese S, Harris J, Masi G (2018) Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis. Neurosci Biobehav Rev 84:359–367. https://doi.org/10.1016/j.neubiorev.2017.08.010
Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE et al (2012) R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry 72(5):405–413. https://doi.org/10.1016/j.biopsych.2012.03.022
MacDonald JR, Hill JD, Tarnopolsky MA (2002) Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 59(12):1876–1880. https://doi.org/10.1212/01.WNL.0000037481.08283.51
Manor I, Rozen S, Zemishlani Z, Weizman A, Zalsman G (2011) When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations. Clin Neuropharmacol 34(4):148–154. https://doi.org/10.1097/WNF.0b013e3182206dc1
Marazziti D, Della Vecchia A, Mucci F (2020) Le demenze. In: Marazziti D (ed) Psicofarmacoterapia clinica, VI edizione. Giovanni Fioriti Editore, Roma, pp 327–342
Markowitz JS, Patrick KS (2008) Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol 28(3 Suppl 2):54–61. https://doi.org/10.1097/JCP.0b013e3181733560
Markowitz JS, Straughn AB, Patrick KS (2003) Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 23(10):1281–1299. https://doi.org/10.1592/phco.23.12.1281.32697
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (2006) A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16(6):687–698. https://doi.org/10.1089/cap.2006.16.687
Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ (2009) The psychostimulant d-threo-(R, R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Pharmazie 64(2):123–125
Martinez-Raga J, Knecht C, de Alvaro R (2015) Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat 11:1359–1370
Menza MA, Kaufman KR, Castellanos A (2000) Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 61(5):378–381. https://doi.org/10.4088/JCP.v61n0510
Michelson D, Adler L, Spencer T, Reimherr FW, West SA et al (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53(2):112–120. https://doi.org/10.1016/S0006-3223(02)01671-2
Migliarese G, Magni E, Cerveri G, Venturi V, Mencacci C (2017) L’ADHD nell’adulto. Psichiatria Oggi 30(1):8–22
Milich R (2001) ADHD combined type and ADHD predominately inattentive type are distinct and unrelated disorders. Clin Psychol Sci Prac 8:463–488
Miller GM (2011) The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 116(2):164–176. https://doi.org/10.1111/j.1471-4159.2010.07109.x
Molina-Carballo A, Checa-Ros A, Muñoz-Hoyos A (2016) Treatments and compositions for attention deficit hyperachyperactivity disorder: a patent review. Expert Opin Ther Pat 26(7):799–814. https://doi.org/10.1080/13543776.2016.1182989
Mucci F, Avella MT, Marazziti D (2019) ADHD with comorbid bipolar disorders: a systematic review of neurobiological, clinical and pharmacological aspects across the lifespan. Curr Med Chem 26(38):6942–6969. https://doi.org/10.2174/0929867326666190805153610
Muit JJ, Bothof N, Kan CC (2020) Pharmacotherapy of ADHD in adults with autism spectrum disorder: effectiveness and side effects. J Atten Disord 24(2):215–225
National Institute for Health and Care Excellence (NICE) (2018) Attention deficit hyperactivity disorder: diagnosis and management (NG87). NICE online. https://www.nice.org.uk/guidance/ng87/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933
Nieves AV, Lang AE (2002) Treatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinil. Clin Neuropharmacol 25(2):111–114. https://doi.org/10.1097/00002826-200203000-00010
Paccosi S, Cresci B, Pala L, Rotella CM, Parenti A (2020) Obesity therapy: how and why? Curr Med Chem 27(2):174–186
Panizzon L (1944) La preparazione di piridil- e piperidil- arilacetonitrili e di alcuni prodotti di trasformazione (parte Ia). Helv Chim Acta 27(1):1748–1756. https://doi.org/10.1002/hlca.194402701222
Perrine DM, Ross JT, Nervi SJ, Zimmerman RHA (2000) Short one-pot synthesis of bupropion (zyban, wellbutrin). J Chem Educ 77(11):1479. https://doi.org/10.1021/ed077p1479
Philpot K, Smith Y (2006) CART peptide and the mesolimbic dopamine system. Peptides 27(8):1987–1992. https://doi.org/10.1016/j.peptides.2005.11.028
Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43(2):434–442. https://doi.org/10.1093/ije/dyt261
Ramos BP, Arnsten AFT (2007) Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 113:523–536
Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T (2016) The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs 30(7):603–628. https://doi.org/10.1007/s40263-016-0349-0
Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC et al (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1–19. https://doi.org/10.1016/j.drugalcdep.2014.12.005
Retz W, Stieglitz RD, Corbisiero S, Retz-Junginger P, Rösler M (2012) Emotional dysregulation in adult ADHD: what is the empirical evidence? Expert Rev Neurother 12(10):1241–1251. https://doi.org/10.1586/ern.12.109
Riediger C, Schuster T, Barlinn K, Maier S, Weitz J, Siepmann T (2017) Adverse effects of antidepressants for chronic pain: a systematic review and meta-analysis. Front Neurol 8:307
Roberts SM, DeMott RP, James RC (1997) Adrenergic modulation of hepatotoxicity. Drug Metab Rev 29(1–2):329–353. https://doi.org/10.3109/03602539709037587
Robertson P, DeCory HH, Madan A, Parkinson A (2000) In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28(6):664–671
Ross RG (2006) Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 163(7):1149–1152. https://doi.org/10.1176/ajp.2006.163.7.1149
Rubio G, López-Muñoz F, Álamo C, Arias A (1998) Alteraciones cardiovasculares durante el tratamiento del síndrome de abstinencia a opiáceos con fármacos alfa-2 agonistas. Rev Clin Esp 198:260–261
Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child: Care. Health Dev 32:575–583
Sauer JM, Ring BJ, Witcher JW (2005) Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44(6):571–590. https://doi.org/10.2165/00003088-200544060-00002
Scheffer RE, Kowatch RA, Carmody T, Rush AJ (2005) Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 162(1):58–64. https://doi.org/10.1176/appi.ajp.162.1.58
Seale JP, Dittmer T, Sigman EJ, Clemons H, Johnson JA (2014) Combined abuse of clonidine and amitriptyline in a patient on buprenorphine maintenance treatment. J Addict Med 8(6):476–478
Spencer TJ, Biederman J, Wilens T (2004) Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27(2):373–383. https://doi.org/10.1016/j.psc.2003.12.001
Spencer TJ, Biederman J, Mick E (2007) Attentiondeficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 32(6):631–642. https://doi.org/10.1093/jpepsy/jsm005
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N et al (2013) Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. J Clin Psychiatry 74(9):902–917. https://doi.org/10.4088/JCP.12r08287
Spencer RC, Devilbiss DM, Berridge CW (2015) The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol Psychiatry 77(11):940–950. https://doi.org/10.1016/j.biopsych.2014.09.013
Stahl SM (2017) Stahl’s essential psychopharmacology: prescriber’s guide, 5th edn. Cambridge University Press, Cambridge
Steinberg S, Chouinard G (1985) A case of mania associated with tomoxetine. Am J Psychiatry 142(12):1517–1518. https://doi.org/10.1176/ajp.142.12.1517
Strange BC (2008) Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat 4(3):499–506. https://doi.org/10.2147/NDT.S1711
Taylor FB, Russo J (2001) Comparing guanfacine and dextroamphetamine for the treatment of adult attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol 21(2):223–228. https://doi.org/10.1097/00004714-200104000-00015
Taylor D, Kapur S, Paton C, Maudsley H (2012) The Maudsley prescribing guidelines in psychiatry, 12th edn. Wiley-Blackwell, Chichester
Todor I, Popa A, Neag M, Muntean D, Bocsan C et al (2016) Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Sci 19(2):198–207. https://doi.org/10.18433/J3H03R
Türkoğlu S (2015) Serotonin syndrome with sertraline and methylphenidate in an adolescent. Clin Neuropharmacol 38(2):65–66. https://doi.org/10.1097/WNF.0000000000000075
Uhlén S, Muceniece R, Rangel N, Tiger G, Wikberg JE (1995) Comparison of the binding activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig. Pharmacol Toxicol 76:353–356
Underhill SM, Wheeler DS, Li M, Watts SD, Ingram SL, Amara SG (2014) Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons. Neuron 83(2):404–416. https://doi.org/10.1016/j.neuron.2014.05.043
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002) Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 6(Suppl. 1):31–43. https://doi.org/10.1177/070674370200601S05
Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A et al (2007) Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129:397–410
Wender PH, Wolf LE, Wasserstein J (2001) Adults with ADHD. An overview. Ann NY Acad Sci 931:1–16. https://doi.org/10.1111/j.1749-6632.2001.tb05770.x
Westover AN, Halm EA (2012) Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovasc Disord 12:41. https://doi.org/10.1186/1471-2261-12-41
Weyandt LL, Iwaszuk W, Fulton K, Ollerton M, Beatty N, Fouts H et al (2003) The internal restlessness scale: performance of college students with and without ADHD. J Learn Disabil 36(4):382–389
Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL et al (2008) Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 96(1–2):145–154. https://doi.org/10.1016/j.drugalcdep.2008.02.009
Williard RL, Middaugh LD, Zhu HJ, Patrick KS (2007) Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol 18(1):39–51. https://doi.org/10.1097/FBP.0b013e3280143226
Wingo AP, Ghaemi SN (2007) A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. J Clin Psychiatry 68(11):1776–1784. https://doi.org/10.4088/JCP.v68n1118
Wolraich M, Brown L, Brown RT et al (2011) Subcommittee on attention-deficit/hyperactivity disorder; steering committee on quality improvement and management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5):1007–1022
Wood S, Sage JR, Shuman T, Anagnostaras SG (2013) Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol Rev 66(1):193–221. https://doi.org/10.1124/pr.112.007054
Xavier C, Blanco-Silvente L, Cunill R (2018) Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 8(8):CD007813. https://doi.org/10.1002/14651858.CD007813.pub3
Zeni CP, Tramontina S, Ketzer CR, Pheula GF, Rohde LA (2009) Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention- deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol 19(5):553–561. https://doi.org/10.1089/cap.2009.0037
Funding
None.
Author information
Authors and Affiliations
Contributions
FM, BC, SB, ADV, AP and GP performed literature research, FM, GP and DM wrote the manuscript. FM, DM, AP revised the manuscript for intellectual content.
Corresponding author
Ethics declarations
Conflict of interests
The authors declare that they have no conflict of interest.
Ethical approval
This review of the literature does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mucci, F., Carpita, B., Pagni, G. et al. Lifetime evolution of ADHD treatment. J Neural Transm 128, 1085–1098 (2021). https://doi.org/10.1007/s00702-021-02336-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-021-02336-w